Thrombophilias in Pregnancy

Hematology/Oncology Clinics of North America

Volumn 25, Issue 2, 2011, Pages 323-333

  Battinelli, E M ^a   Bauer, K A ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulation; Hypercoagulable; Pregnancy; Thrombophilias; Venous thromboembolic events

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN; CARDIOLIPIN ANTIBODY; ENOXAPARIN; FOLIC ACID; HEPARIN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYTIC INHIBITOR; UNCLASSIFIED DRUG;

ACTIVATED PROTEIN C RESISTANCE; ADD ON THERAPY; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG USE; FETUS WASTAGE; GENE MUTATION; HELLP SYNDROME; HETEROZYGOSITY; HORMONE DETERMINATION; HUMAN; HYPERHOMOCYSTEINEMIA; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; LOW DRUG DOSE; LUNG EMBOLISM; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM;

ABORTION, SPONTANEOUS; ABRUPTIO PLACENTAE; ANTIPHOSPHOLIPID SYNDROME; FACTOR V; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; STILLBIRTH; VENOUS THROMBOEMBOLISM;

EID: 79953059216     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.02.003     Document Type: Review

References (62)

1. Heit J.A., Kobbervig C.E., James A.H., et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med 2005, 143(10):697-706.
2. James A.H., Jamison M.G., Brancazio L.R., et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol 2006, 194(5):1311-1315.
3. James A.H., Bushnell C.D., Jamison M.G., et al. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005, 106(3):509-516.
4. James A.H., Jamison M.G., Biswas M.S., et al. Acute myocardial infarction in pregnancy: a United States population-based study. Circulation 2006, 113(12):1564-1571.
5. Ronsmans C., Graham W.J. Maternal mortality: who, when, where, and why. Lancet 2006, 368(9542):1189-1200.
6. Macklon N.S., Greer I.A., Bowman A.W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol 1997, 104(2):191-197.
7. Goldhaber S.Z., Tapson V.F. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 2004, 93(2):259-262.
8. Ginsberg J.S., Brill-Edwards P., Burrows R.F., et al. Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost 1992, 67(5):519-520.
9. Kovacevich G.J., Gaich S.A., Lavin J.P., et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000, 182(5):1089-1092.
10. Danilenko-Dixon D.R., Heit J.A., Silverstein M.D., et al. Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. Am J Obstet Gynecol 2001, 184(2):104-110.
11. Bremme K.A. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003, 16(2):153-168.
12. Antovic J.P., Rafik Hamad R., Antovic A., et al. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb Haemost 2002, 88(4):644-647.
13. Cerneca F., Ricci G., Simeone R., et al. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur J Obstet Gynecol Reprod Biol 1997, 73(1):31-36.
14. Pabinger I., Grafenhofer H., Kyrle P.A., et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002, 100(3):1060-1062.
15. Pabinger I., Grafenhofer H., Kaider A., et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005, 3(5):949-954.
16. Gerhardt A., Scharf R.E., Beckmann M.W., et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000, 342(6):374-380.
17. Middeldorp S., Libourel E.J., Hamulyak K., et al. The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. Br J Haematol 2001, 113(2):553-555.
18. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369(6475):64-67.
19. Ridker P.M., Miletich J.P., Stampfer M.J., et al. Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995, 92(10):2800-2802.
20. Poort S.R., Rosendaal F.R., Reitsma P.H., et al. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996, 88(10):3698-3703.
21. Cotter A.M., Molloy A.M., Scott J.M., et al. Elevated plasma homocysteine in early pregnancy: a risk factor for the development of severe preeclampsia. Am J Obstet Gynecol 2001, 185(4):781-785.
22. van der Meer F.J., Koster T., Vandenbroucke J.P., et al. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997, 78(1):631-635.
23. Ray J.G., Shmorgun D., Chan W.S. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002, 32(2):51-58.
24. Dilley A., Austin H., El-Jamil M., et al. Genetic factors associated with thrombosis in pregnancy in a United States population. Am J Obstet Gynecol 2000, 183(5):1271-1277.
25. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006, 132(2):171-196.
26. Benedetto C., Marozio L., Tavella A.M., et al. Coagulation disorders in pregnancy: acquired and inherited thrombophilias. Ann N Y Acad Sci 2010, 1205:106-117.
27. Kutteh W.H. Antiphospholipid antibodies and reproduction. J Reprod Immunol 1997, 35(2):151-171.
28. Long A.A., Ginsberg J.S., Brill-Edwards P., et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 1991, 66(5):520-524.
29. Saftlas A.F., Olson D.R., Franks A.L., et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990, 163(2):460-465.
30. Brenner B., Lanir N., Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996, 92(4):999-1001.
31. van Pampus M.G., Dekker G.A., Wolf H., et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999, 180(5):1146-1150.
32. Kosmas I.P., Tatsioni A., Ioannidis J.P. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003, 21(7):1221-1228.
33. Dudding T.E., Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004, 91(4):700-711.
34. Lin J., August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005, 105(1):182-192.
35. Dudding T., Heron J., Thakkinstian A., et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: a genetic association study and meta-analysis. J Thromb Haemost 2008, 6(11):1869-1875.
36. D'Elia A.V., Driul L., Giacomello R., et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Invest 2002, 53(2):84-87.
37. Morrison E.R., Miedzybrodzka Z.H., Campbell D.M., et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002, 87(5):779-785.
38. Silver R.M., Zhao Y., Spong C.Y., et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010, 115(1):14-20.
39. Ray J.G., Laskin C.A. Folic acid and homocyst(e)ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta 1999, 20(7):519-529.
40. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002, 101(1):6-14.
41. Roque H., Paidas M.J., Funai E.F., et al. Maternal thrombophilias are not associated with early pregnancy loss. Thromb Haemost 2004, 91(2):290-295.
42. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003, 361(9361):901-908.
43. Meinardi J.R., Middeldorp S., de Kam P.J., et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999, 130(9):736-739.
44. Tormene D., Simioni P., Prandoni P., et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999, 82(4):1237-1239.
45. Kocher O., Cirovic C., Malynn E., et al. Obstetric complications in patients with hereditary thrombophilia identified using the LCx microparticle enzyme immunoassay: a controlled study of 5,000 patients. Am J Clin Pathol 2007, 127(1):68-75.
46. Sottilotta G., Oriana V., Latella C., et al. Genetic prothrombotic risk factors in women with unexplained pregnancy loss. Thromb Res 2006, 117(6):681-684.
47. Preston F.E., Rosendaal F.R., Walker I.D., et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348(9032):913-916.
48. Simioni P., Tormene D., Prandoni P., et al. Pregnancy-related recurrent events in thrombophilic women with previous venous thromboembolism. Thromb Haemost 2001, 86(3):929.
49. Brill-Edwards P., Ginsberg J.S., Gent M., et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000, 343(20):1439-1444.
50. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133(Suppl 6):844S-886S.
51. Hohlagschwandtner M., Unfried G., Heinze G., et al. Combined thrombophilic polymorphisms in women with idiopathic recurrent miscarriage. Fertil Steril 2003, 79(5):1141-1148.
52. Gris J.C., Mercier E., Quere I., et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004, 103(10):3695-3699.
53. Folkeringa N., Brouwer J.L., Korteweg F.J., et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol 2007, 136(4):656-661.
54. Coppens M., Folkeringa N., Teune M.J., et al. Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. J Thromb Haemost 2007, 5(7):1444-1448.
55. Rai R., Cohen H., Dave M., et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314(7076):253-257.
56. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996, 174(5):1584-1589.
57. Farquharson R.G., Quenby S., Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100(3):408-413.
58. Badawy A.M., Khiary M., Sherif L.S., et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol 2008, 28(3):280-284.
59. Warren J.E., Simonsen S.E., Branch D.W., et al. Thromboprophylaxis and pregnancy outcomes in asymptomatic women with inherited thrombophilias. Am J Obstet Gynecol 2009, 200(3):281.e1-281.e5.
60. Dolitzky M., Inbal A., Segal Y., et al. A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages. Fertil Steril 2006, 86(2):362-366.
61. Laskin C.A., Spitzer K.A., Clark C.A., et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009, 36(2):279-287.
62. Mantha S., Bauer K.A., Zwicker J.I. Low molecular weight heparin to achieve live birth following unexplained pregnancy loss: a systematic review. J Thromb Haemost 2010, 8(2):263-268.